Abstract
Advanced ovarian cancer is the most serious among gynecological malignancies and is associated with 35% five-year overall survival. Surgery is the first therapeutic indication, and the absence of remaining macroscopic lesions is the most important prognostic factor. However, tumor dissemination over the whole abdominal cavity largely contributes to the difficulty of complete surgical resection. Consequently, any therapeutic approach that may complete surgical resection should improve patient survival. Considering that some sites are not suitable for surgery because of their close location to vital organs, intraoperative photodynamic therapy (ioPDT) appears to be a complementary therapeutic approach to surgery to obtain the lowest residual disease.
Relevant in vivo cancer models that closely resemble human ovarian cancer are essential for preclinical research of alternative antitumor therapeutic strategies. Thus, we propose a comprehensive protocol to set up an orthotopic ovarian xenograft in mice leading to peritoneal carcinomatosis that could be harnessed for antitumor therapeutic application and evaluation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953
Janco JMT, Glaser G, Kim B, McGree ME, Weaver AL, Cliby WA, Dowdy SC, Bakkum-Gamez JN (2015) Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol Oncol 138:70–77
Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, Scambia G (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13:1156–1161
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221:124–132
Chereau E, Lavoue V, Ballester M, Coutant C, Selle F, Cortez A, Daraï E, Leveque J, Rouzier R (2011) External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. Anticancer Res 31:4469–4474
Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21:75–80
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol 20:1248–1259
Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69:103–108
Eisenkop SM, Spirtos NM, Friedman RL, Lin W-CM, Pisani AL, Perticucci S (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90:390–396
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol Off J Am Soc Clin Oncol 9:1138–1150
Fujwara K, Yoshino K, Enomoto T, Fujita M, Ueda Y, Miyatake T, Kimura T, Muraji M, Fujita H, Kimura T et al (2011) Usefulness of computed tomography in predicting cytoreductive surgical outcomes for ovarian cancer. Arch Gynecol Obstet 284:1501–1507
Glaser G, Torres M, Kim B, Aletti G, Weaver A, Mariani A, Hartmann L, Cliby W (2013) The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer. Gynecol Oncol 130:280–283
Tochner Z, Mitchell JB, Smith P, Harrington F, Glatstein E, Russo D, Russo A (1986) Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer 53:733–736
DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM, Glatstein E (1993) Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 25:445–457
Hahn SM (2006) A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 12:2517–2525
Almerie MQ, Gossedge G, Wright KE, Jayne DG (2017) Treatment of peritoneal carcinomatosis with photodynamic therapy: Systematic review of current evidence. Photodiagn Photodyn Ther 20:276–286
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet Lond Engl 384:1376–1388
Vang R, Shih I-M, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62:44–58
George SHL, Garcia R, Slomovitz BM (2016) Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. Front Oncol 6:108
Dubeau L (1999) The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 72:437–442
Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL, Sauver JS, Bakkum-Gamez JN (2014) Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 135:423–427
Madsen C, Baandrup L, Dehlendorff C, Kjaer SK (2015) Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 94:86–94
Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236
Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 109:3921–3926
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Michy, T., Bernard, C., Coll, JL., Josserand, V. (2022). An Orthotopic Murine Model of Peritoneal Carcinomatosis of Ovarian Origin for Intraoperative PDT . In: Broekgaarden, M., Zhang, H., Korbelik, M., Hamblin, M.R., Heger, M. (eds) Photodynamic Therapy. Methods in Molecular Biology, vol 2451. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2099-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2099-1_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2098-4
Online ISBN: 978-1-0716-2099-1
eBook Packages: Springer Protocols